Pharmacokinetic Study in Healthy VolunteersFISEKIN-1NCT06796374
A Comparison of Fisetin Kinetics in Young and Old Adults
A study testing Fisetin - Fasted condition and Fisetin - Fed condition in people with Pharmacokinetic Study in Healthy Volunteers, run by University Medicine Greifswald at 1 site in Germany.
Trial summary
This study investigates the differences in the kinetic parameters of fisetin in two cohorts of healthy volunteers: Cohort 1) volunteers aged 18-30 years (n = 40) Cohort 2) volunteers aged 65 years or older (n = 40) The purpose of this study is: 1. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pharmacokinetic Study in Healthy Volunteers
- What is being tested?
- Fisetin - Fasted condition and Fisetin - Fed condition
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteGermany
- Study dates
- 31 Mar 2026to 31 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- any sex
- age between 18 and 30 years or ≥ 65 years
- understands the study purpose and design
- contractually capable and provides signed informed consent form
- healthy condition or mild and/or well-treated forms of allergies, asthma, hypertension, and orthopedic diseases
- a maximum of 3 chronically taken drugs
Who cannot join
- BMI > 30 kg/m2 and < 18 kg/m2
- body weight < 48 kg
- women in young cohort: known pregnancy or lactation period; positive urine pregnancy test at screening or kinetic visit
- men: hemoglobin < 8,3 mmol/l women: hemoglobin < 7,3 mmol/l
- elevated liver function tests (1 or more of ALAT, ASAT, yGT, Bilirubin > 2x ULN)
- reduced renal function (eGFRMDRD < 60 ml/min/1,7 m2)
Show all 17Show fewer
- QTcF > 450 ms in screening ECG
- psychiatric disease requiring recent or actual treatment
- drug dependency at the time of visit
- use of recreational drugs more than twice a week
- any known hypersensitivity or allergic reactions to fisetin
- history of severe hypersensitivity reactions and/or anaphylaxis
- poor venous conditions that make it impossible to place a peripheral venous catheter and regularly draw blood through it
- intake of drugs undergoing extensive metabolism via CYP1A2, CYP2D6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and/or Pgp and with narrow (monitoring-requiring) therapeutic range during the past seven days if the duration of intake was at least two days
- intake of COMT-inhibitors during the past seven days if the duration of intake was at least two days
- intake of drugs or dietary supplements containing fisetin within the two days before or during the kinetic visits
- individuals who have eaten food with high fisetin content in the two days before the kinetic visits (e.g. strawberry, apple, persimmon, grape, mango, kiwi, peach, tomato, onion, lotus roots, kale, cucumber; processed products, e.g. wine)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
Department of Clinical Pharmacology, Institute of Pharmacology at the Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald
Greifswald
Stefan Engeli, Prof., +49 3834 86 56 33, stefan.engeli@med.uni-greifswald.de
About this study
Official title: A Comparison of Fisetin Kinetics in Young and Old Adults - FISEKIN-1
This study investigates the differences in the kinetic parameters of fisetin in two cohorts of healthy volunteers:
Cohort 1) volunteers aged 18-30 years (n = 40) Cohort 2) volunteers aged 65 years or older (n = 40)
Read more
The purpose of this study is:
- To describe the fisetin kinetics after a single dose oral administration in older age.
- To compare the fisetin kinetics after a single dose oral administration in old and young age.
FISEKIN-1 is designed as a four-arm study protocol. As well as two different age groups (18-30 years vs. 65 years and older), we want to compare fisetin kinetic parameters in fasted and fed condition:
Arm 1) 500 mg fisetin (1x 5 capsule), fasted condition, cohort 1: young age Arm 2) 500 mg fisetin (1x 5 capsule), fasted condition, cohort 2: old age Arm 3) 500 mg fisetin (1x 5 capsule), fed condition, cohort 1: young age Arm 4) 500 mg fisetin (1x 5 capsule), fed condition, cohort 2: old age
Read the detailed description
The study is designed as an open-label, two-cohorts (young vs. old), four-arm, cross-over, single oral dose protocol.
A single oral dose of fisetin will be administered as capsules with 240 ml of still water in the overnight fasting condition (arm 1; 2) or in fed condition (arm 3; 4).
The arms will be conducted in each participant in random order with a wash-out period of at least one week between each arm.
Fed condition (arm 3; 4): We will serve a high-caloric and high-fat meal based on the recommendation of the FDA (Food and Drug Administration) for food-effect studies. This meal will contain two slices of toast with butter, two eggs fried in butter, approx. 113 g hash brown potatoes and 240 ml whole milk.
A total of 24 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 3.5; 4.0; 4.5; 5.0; 5.5; 6.0; 6.5; 7.0; 7.5; 8.0; 9.0; 10.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and its metabolites.
The total amount of blood collected for each participant and each arm is 164 ml at the kinetic visits and 12 ml at the screening visit.
After intake of fisetin, participants will drink 200 ml of sparkling water every hour to stimulate gastrointestinal peristalsis and to promote transport of the capsule. After 2 hours, the participants may drink a cup of tea or coffee and after 4 hours they will be served a meal low in fisetin content. Urine will be collected during the first 10 hours after fisetin administration. Monitoring of blood pressure and heart rate will take place for the first 4 hours after administration. Volunteers will stay in the Clinical Research Unit of the Institute of Pharmacology for the first 10 hours after administration.
- Being tested
- Fisetin - Fasted condition, Fisetin - Fed condition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fisetin - Fasted conditionDietary supplement
A single oral dose of 500 mg fisetin (as Novusetin®) will be administered as 5 capsules with 240 ml of still water in the overnight fasting condition:
A total of 24 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 3.5; 4.0; 4.5; 5.0; 5.5; 6.0; 6.5; 7.0; 7.5; 8.0; 9.0; 10.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 164 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration.
Fisetin - Fed conditionDietary supplement
A single oral dose of 500 mg fisetin (as Novusetin®) will be administered as 5 capsules with 240 ml of still water in fed condition:
Participants will eat a high-caloric and high-fat meal based on the recommendation of the FDA (Food and Drug Administration) for food-effect studies. This meal will contain two slices of toast with butter, two eggs fried in butter, approx. 113 g hash brown potatoes and 240 ml whole milk.
A total of 24 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 3.5; 4.0; 4.5; 5.0; 5.5; 6.0; 6.5; 7.0; 7.5; 8.0; 9.0; 10.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 164 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration.
| Study group | Role | What they receive |
|---|---|---|
| Arm 2: Fisetin, fasted condition - Cohort 2: old age (≥ 65 years) | Active comparator | Not described Receives: Dietary Supplement: Fisetin - Fasted condition |
| Arm 4: Fisetin, fed condition - Cohort 2: old age (≥ 65 years) | Active comparator | Not described Receives: Dietary Supplement: Fisetin - Fed condition |
| Arm 1: Fisetin, fasted condition - Cohort 1: young age (18-30 years) | Active comparator | Not described Receives: Dietary Supplement: Fisetin - Fasted condition |
| Arm 3: Fisetin, fed condition - Cohort 1: young age (18-30 years) | Active comparator | Not described Receives: Dietary Supplement: Fisetin - Fed condition |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fisetin plasma concentration arm 1 vs. arm 2
Difference of fisetin plasma concentrations between the young and old cohort, expressed as area under the curve (AUC0-10h).
Measured: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Difference of fisetin plasma concentrations between the young and old cohort, expressed as area under the curve (AUC0-10h).
Measured: 10 hours
Secondary outcomes (24)
Fisetin metabolites plasma concentration arm 1 vs. arm 2
Difference in plasma concentrations of fisetin metabolites between the young and old cohort, expressed as area under the curve (AUC0-10h).
Measured: 10 hours
Fisetin metabolites plasma concentration arm 3 vs. arm 4
Difference in plasma concentrations of fisetin metabolites between the young and old cohort, expressed as area under the curve (AUC0-10h).
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Difference plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as maximum plasma concentration (Cmax).
Measured: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as maximum plasma concentration (Cmax).
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as time at maximum concentration (Tmax).
Measured: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as time at maximum concentration (Tmax).
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as total clearance.
Measured: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as total clearance.
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as renal clearance.
Measured: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as renal clearance.
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as apparent volume of distribution.
Measured: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between the young and old cohort, expressed as apparent volume of distribution.
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Difference of fisetin plasma concentrations between arm 1 and arm 3, expressed as area under the curve (AUC0-10h).
Measured: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Difference of fisetin plasma concentrations between arm 2 and arm 4, expressed as area under the curve (AUC0-10h).
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 1 and arm 3, expressed as maximum plasma concentration (Cmax).
Measured: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 2 and arm 4, expressed as maximum plasma concentration (Cmax).
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 1 and arm 3, expressed as time at maximum concentration (Tmax).
Measured: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 2 and arm 4, expressed as time at maximum concentration (Tmax).
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 1 and arm 3, expressed as total clearance.
Measured: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 2 and arm 4, expressed as total clearance.
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 1 and arm 3, expressed as renal clearance.
Measured: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 2 and arm 4, expressed as renal clearance.
Measured: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 1 and arm 3, expressed as apparent volume of distribution.
Measured: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Difference in plasma concentrations of fisetin and fisetin metabolites between arm 2 and arm 4, expressed as apparent volume of distribution.
Measured: 10 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2025
- Study start31 Mar 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion31 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pharmacokinetic Study in Healthy VolunteersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The kinetic study will be designed as an open-label, two-cohorts (young vs. old), four-arm, randomized cross-over, single oral dose protocol.
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Medicine Greifswald
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06796374
- Sponsor's protocol ID
- IPHA-2025-010
- Acronym
- FISEKIN-1
- Status last verified
- Mar 2026
- First submitted
- 13 Jan 2025
- Last updated
- 6 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparison of Fisetin Kinetics in Young and Old Adults - FISEKIN-1
- ClinicalTrials.gov ID
- NCT06796374
- Acronym / sponsor ID
- FISEKIN-1 / IPHA-2025-010
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University Medicine GreifswaldUniversity, hospital or other
- Study start
- 31 Mar 2026 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 31 Jul 2027 (estimated)
- First posted
- 28 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates the differences in the kinetic parameters of fisetin in two cohorts of healthy volunteers:
Cohort 1) volunteers aged 18-30 years (n = 40) Cohort 2) volunteers aged 65 years or older (n = 40)
The purpose of this study is:
- To describe the fisetin kinetics after a single dose oral administration in older age.
- To compare the fisetin kinetics after a single dose oral administration in old and young age.
FISEKIN-1 is designed as a four-arm study protocol. As well as two different age groups (18-30 years vs. 65 years and older), we want to compare fisetin kinetic parameters in fasted and fed condition:
Arm 1) 500 mg fisetin (1x 5 capsule), fasted condition, cohort 1: young age Arm 2) 500 mg fisetin (1x 5 capsule), fasted condition, cohort 2: old age Arm 3) 500 mg fisetin (1x 5 capsule), fed condition, cohort 1: young age Arm 4) 500 mg fisetin (1x 5 capsule), fed condition, cohort 2: old age
Detailed description
The study is designed as an open-label, two-cohorts (young vs. old), four-arm, cross-over, single oral dose protocol.
A single oral dose of fisetin will be administered as capsules with 240 ml of still water in the overnight fasting condition (arm 1; 2) or in fed condition (arm 3; 4).
The arms will be conducted in each participant in random order with a wash-out period of at least one week between each arm.
Fed condition (arm 3; 4): We will serve a high-caloric and high-fat meal based on the recommendation of the FDA (Food and Drug Administration) for food-effect studies. This meal will contain two slices of toast with butter, two eggs fried in butter, approx. 113 g hash brown potatoes and 240 ml whole milk.
A total of 24 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 3.5; 4.0; 4.5; 5.0; 5.5; 6.0; 6.5; 7.0; 7.5; 8.0; 9.0; 10.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and its metabolites.
The total amount of blood collected for each participant and each arm is 164 ml at the kinetic visits and 12 ml at the screening visit.
After intake of fisetin, participants will drink 200 ml of sparkling water every hour to stimulate gastrointestinal peristalsis and to promote transport of the capsule. After 2 hours, the participants may drink a cup of tea or coffee and after 4 hours they will be served a meal low in fisetin content. Urine will be collected during the first 10 hours after fisetin administration. Monitoring of blood pressure and heart rate will take place for the first 4 hours after administration. Volunteers will stay in the Clinical Research Unit of the Institute of Pharmacology for the first 10 hours after administration.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- The kinetic study will be designed as an open-label, two-cohorts (young vs. old), four-arm, randomized cross-over, single oral dose protocol.
| Arm | Type | Receives |
|---|---|---|
| Arm 2: Fisetin, fasted condition - Cohort 2: old age (≥ 65 years) | Active comparator | Dietary Supplement: Fisetin - Fasted condition |
| Arm 4: Fisetin, fed condition - Cohort 2: old age (≥ 65 years) | Active comparator | Dietary Supplement: Fisetin - Fed condition |
| Arm 1: Fisetin, fasted condition - Cohort 1: young age (18-30 years) | Active comparator | Dietary Supplement: Fisetin - Fasted condition |
| Arm 3: Fisetin, fed condition - Cohort 1: young age (18-30 years) | Active comparator | Dietary Supplement: Fisetin - Fed condition |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- any sex
- age between 18 and 30 years or ≥ 65 years
- understands the study purpose and design
- contractually capable and provides signed informed consent form
- healthy condition or mild and/or well-treated forms of allergies, asthma, hypertension, and orthopedic diseases
Key exclusion criteria (17 listed)
- BMI > 30 kg/m2 and < 18 kg/m2
- body weight < 48 kg
- women in young cohort: known pregnancy or lactation period; positive urine pregnancy test at screening or kinetic visit
- men: hemoglobin < 8,3 mmol/l women: hemoglobin < 7,3 mmol/l
- elevated liver function tests (1 or more of ALAT, ASAT, yGT, Bilirubin > 2x ULN)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fisetin - Fasted conditionA single oral dose of 500 mg fisetin (as Novusetin®) will be administered as 5 capsules with 240 ml of still water in the overnight fasting condition: A total of 24 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 3.5; 4.0; 4.5; 5.0; 5.5; 6.0; 6.5; 7.0; 7.5; 8.0; 9.0; 10.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 164 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration. | Dietary supplement | Arm 1: Fisetin, fasted condition - Cohort 1: young age (18-30 years), Arm 2: Fisetin, fasted condition - Cohort 2: old age (≥ 65 years) |
| Fisetin - Fed conditionA single oral dose of 500 mg fisetin (as Novusetin®) will be administered as 5 capsules with 240 ml of still water in fed condition: Participants will eat a high-caloric and high-fat meal based on the recommendation of the FDA (Food and Drug Administration) for food-effect studies. This meal will contain two slices of toast with butter, two eggs fried in butter, approx. 113 g hash brown potatoes and 240 ml whole milk. A total of 24 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 3.5; 4.0; 4.5; 5.0; 5.5; 6.0; 6.5; 7.0; 7.5; 8.0; 9.0; 10.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 164 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration. | Dietary supplement | Arm 3: Fisetin, fed condition - Cohort 1: young age (18-30 years), Arm 4: Fisetin, fed condition - Cohort 2: old age (≥ 65 years) |
Primary outcome
Fisetin plasma concentration arm 1 vs. arm 2
Time frame: 10 hours
Difference of fisetin plasma concentrations between the young and old cohort, expressed as area under the curve (AUC0-10h).
Fisetin plasma concentration arm 3 vs. arm 4
Time frame: 10 hours
Difference of fisetin plasma concentrations between the young and old cohort, expressed as area under the curve (AUC0-10h).
24 secondary outcomes
Fisetin metabolites plasma concentration arm 1 vs. arm 2
Time frame: 10 hours
Fisetin metabolites plasma concentration arm 3 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Time frame: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Time frame: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Time frame: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Time frame: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 2
Time frame: 10 hours
Fisetin plasma concentration arm 3 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Time frame: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Time frame: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Time frame: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Time frame: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Time frame: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Time frame: 10 hours
Fisetin plasma concentration arm 1 vs. arm 3
Time frame: 10 hours
Fisetin plasma concentration arm 2 vs. arm 4
Time frame: 10 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Pharmacokinetic Study in Healthy Volunteers
Not yet recruitingPhase 1
Pharmacokinetics, Safety and Tolerability of Single Sequential and Multiple Intravenous Infusions of Ulinastatin for Injection in Healthy Chinese Participants
Healthy Participants, Ulinastatin
Not yet recruitingPhase 1
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy Participants
Not yet recruitingPhase 1
A Study to Investigate the Pharmacokinetics and Safety of KM04 Compared to United States (US)-Gonal-f Revised Formulation Female (RFF) Redi-ject and European Union (EU)-Gonal-f in Healthy Adult Female Volunteers
Healthy Female Adult Volunteers
RecruitingPhase 1
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
Healthy Adult Participants
Not yet recruitingPhase 1
A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants
Overweight, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fisetin - Fasted condition and Fisetin - Fed condition in people with Pharmacokinetic Study in Healthy Volunteers, run by University Medicine Greifswald at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stefan Engeli, Prof. (+49 3834 86 56 33, stefan.engeli@med.uni-greifswald.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fisetin plasma concentration arm 1 vs. arm 2 (time frame: 10 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.